NATCOPHARM

Natco Pharma Share Price

₹1,416.95 -59.85 (-4.05%)

22 Dec, 2024 21:56

SIP TrendupStart SIP in NATCOPHARM

Start SIP

Performance

  • Low
  • ₹1,410
  • High
  • ₹1,482
  • 52 Week Low
  • ₹755
  • 52 Week High
  • ₹1,639
  • Open Price₹1,481
  • Previous Close₹1,477
  • Volume480,121

Investment Returns

  • Over 1 Month + 3.07%
  • Over 3 Month -4.33%
  • Over 6 Month + 18.02%
  • Over 1 Year + 82.09%
SIP Lightning

Smart Investing Starts Here Start SIP with Natco Pharma for Steady Growth!

Invest Now

Natco Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 13
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 25,379
  • P/B Ratio
  • 4.3
  • Average True Range
  • 42.73
  • EPS
  • 108.58
  • Dividend Yield
  • 0.4
  • MACD Signal
  • 15.34
  • RSI
  • 48.45
  • MFI
  • 77.07

Natco Pharma Financials

Natco Pharma Technicals

EMA & SMA

Current Price
₹1,416.95
-59.85 (-4.05%)
pointer
  • stock-down_img
  • Bullish Moving Average 7
  • stock-up_img
  • Bearish Moving Average 9
  • 20 Day
  • ₹1,431.42
  • 50 Day
  • ₹1,415.92
  • 100 Day
  • ₹1,379.38
  • 200 Day
  • ₹1,267.62

Resistance and Support

1436.23 Pivot Speed
  • R3 1,534.22
  • R2 1,507.98
  • R1 1,462.47
  • S1 1,390.72
  • S2 1,364.48
  • S3 1,318.97

What's your outlook on Natco Pharma?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

NATCO Pharma Ltd. is a leading Indian pharmaceutical company specializing in generic and specialty medicines, including oncology, cardiology, and central nervous system therapies. It serves global markets with a focus on affordable and high-quality healthcare solutions.

Natco Pharma has an operating revenue of Rs. 4,560.60 Cr. on a trailing 12-month basis. An annual revenue growth of 47% is outstanding, Pre-tax margin of 42% is great, ROE of 23% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 5% and 18% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 1% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 90 which is a GREAT score indicating consistency in earnings, a RS Rating of 71 which is FAIR indicating the recent price performance, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 50 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Natco Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-12 Quarterly Results & Interim Dividend
2024-08-12 Quarterly Results & Interim Dividend
2024-05-27 Audited Results
2024-02-14 Quarterly Results & Interim Dividend
2023-11-14 Quarterly Results & Interim Dividend
Date Purpose Remarks
2024-11-27 INTERIM Rs.1.50 per share(75%)Second Interim Dividend (RD & XD dates revised)
2024-08-23 INTERIM Rs.3.00 per share(150%)Interim Dividend
2024-02-26 INTERIM Rs.1.25 per share(62.5%)Third Interim Dividend
2023-11-24 INTERIM Rs.1.25 per share(62.5%)Second Interim Dividend
2023-08-22 INTERIM Rs.7.00 per share(350%)Interim Dividend

Natco Pharma F&O

Natco Pharma Shareholding Pattern

49.62%
2.37%
4.23%
17.51%
0%
22.6%
3.67%

About Natco Pharma

  • NSE Symbol
  • NATCOPHARM
  • BSE Symbol
  • 524816
  • ISIN
  • INE987B01026

Similar Stocks to Natco Pharma

Natco Pharma FAQs

Natco Pharma share price is ₹1,416 As on 22 December, 2024 | 21:42

The Market Cap of Natco Pharma is ₹25379 Cr As on 22 December, 2024 | 21:42

The P/E ratio of Natco Pharma is 13 As on 22 December, 2024 | 21:42

The PB ratio of Natco Pharma is 4.3 As on 22 December, 2024 | 21:42

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23